Study summary
Experts set new targets for what a successful meningioma drug must achieve
38.0%of grade 2-3 recurrent meningiomas without growth at 6 months on past drugs
What was tested
A pooled analysis of drug trials for recurrent meningioma by the international RANO working group, to set benchmarks for future trials.
What they found
- With past drugs, 38.0% of recurrent grade 2-3 meningiomas went 6 months without growth.
- Targeted drugs did better (62.0% at 6 months for grade 1 tumors).
- New benchmark set: 49% at 6 months for grade 2-3 tumors.
What it means
Gives new trials a clearer bar to beat, which should make results easier to interpret.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.